# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $5...
Morgan Stanley analyst Vikram Purohit reinstates Genmab (NASDAQ:GMAB) with a Equal-Weight and announces $31 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.
JP Morgan analyst James Gordon downgrades Genmab (NASDAQ:GMAB) from Overweight to Neutral.
TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...